Amgen said a drug combination reduced the risk of death for patients with aggressive lung cancer
Amgen said its drug Imdelltra, combined with AstraZeneca’s Imfinzi as first-line maintenance therapy for extensive-stage small cell lung cancer, reduced the risk of death by 58% in Phase 3 results. Median overall survival was 21.1 months, versus 12.7 months with Imfinzi alone. Amgen Chief Medical Officer Paul Burton said the findings could transform care; Amgen plans to share them with regulators.
More context
Amgen said interim Phase 3 results showed that adding its drug Imdelltra to AstraZeneca’s immunotherapy Imfinzi reduced the risk of death by 58% among patients with extensive-stage small cell lung cancer. In the DeLLphi-305 trial, the combination was used as first-line maintenance treatment for patients whose cancer had not progressed after initial treatment with Imfinzi and chemotherapy. Patients receiving the combination lived a median 21.1 months, while the median for those on Imfinzi by itself was 12.7 months. Amgen said nearly 80% of patients who started the combination were alive at one year, versus 53% of those receiving Imfinzi alone. According to Amgen chief medical officer Paul Burton, the data may reshape the standard of care. The company said it plans to share the results with regulators worldwide.
Was this story useful?
What was the main problem? (optional)
Reporting
- CNBC — Amgen's Imdelltra combo cuts risk of death by 58% in lung cancer
- pluang.com — Amgen's drug combo cuts death risk by 58% in ag... | Pluang
- Moneycontrol — Amgen-AstraZeneca drug combination cut risk of death in small cell lung cancer by 58%
- amgen.com — IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER| Amgen
- Reuters — Amgen drug combined with immunotherapy extends survival in lung cancer trial
- marketscreener.com — Amgen Announces IMDELLTRA in Combination with Imfinzi Reduces Risk of Death in First-Line Extensive Stage Small Cell Lung Cancer | MarketScreener
- briefs.co — Amgen-AZ Combo Extends Lung Cancer Survival
Verifier’s note
The reports say Amgen's Imdelltra plus AstraZeneca's Imfinzi reduced the risk of death by 58% in extensive-stage small cell lung cancer. They were published on October 24, 2026, consistent with the proposed event's timing.